{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:03:11Z","timestamp":1785409391858,"version":"3.56.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study was to (1) determine the incidence of acute kidney injury (AKI) in patients with oncological diseases and identify its probable causes, (2) estimate the pharmacokinetic (PK) parameters in this population, and (3) propose vancomycin dosage regimens to support safer dosing in nontherapeutic drug monitoring settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors conducted a prospective observational cohort study involving 334 adult patients with oncological diseases (406 vancomycin treatment courses) at a tertiary cancer center in Brazil. Vancomycin was administered using a Bayesian AUC\u2013guided protocol. AKI was defined using the RIFLE criteria and adjudicated by a multidisciplinary team to determine probable vancomycin attribution. Linear regression was used to estimate the PK parameters and propose a practical dosing regimen for resource-limited settings without therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>AKI occurred in 15% (62\/406) of vancomycin courses, with 34% of the events occurring within the first 24 hours of therapy initiation. After excluding early-onset and non\u2013drug-related AKI, the incidence of vancomycin-induced acute kidney injury was 4.9%. A wide trough variability (5.35\u201320.11 mg\/L) was observed for AUC values of 400\u2013500 mg*h\/L. Multiple linear regression showed that CrCl, intensive care unit admission, and oncohematological status independently influenced PK parameters. Stratified maintenance dose ranges were described, offering potential guidance for empirical dosing in therapeutic drug monitoring\u2013limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The incidence of vancomycin-induced acute kidney injury in this oncological cohort was 4.9%. CrCl, intensive care unit admission, and type of oncological disease significantly influenced the PK parameters. These findings support the development of context-specific dosing guidance but require external validation before implementation in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001508","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:00:10Z","timestamp":1784120410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin-Induced AKI in Adult Patients With Oncological Diseases: Bridging Diagnostic Criteria Gaps With Tailored Dosing Strategies in a Prospective Cohort Study"],"prefix":"10.1097","author":[{"given":"Diogenes","family":"Coelho","sequence":"first","affiliation":[{"name":"Departments of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Migotto","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Feriani da Silva","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Reghini","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiane","family":"Gama Teixeira","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"de Lima Moreira","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro-RJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Caruso","sequence":"additional","affiliation":[{"name":"Intensive Care Department, AC Camargo Cancer Center, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Fran\u00e7a e Silva","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Telles","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"e01293-17","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1060028014556813","article-title":"A randomized trial of loading vancomycin in the emergency department","volume":"49","author":"Rosini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","article-title":"Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity","volume":"123","author":"Pritchard","year":"2010","journal-title":"Am J Med"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000001075","article-title":"Area-under-curve-guided versus trough-guided monitoring of vancomycin and its impact on nephrotoxicity: a systematic review and meta-analysis","volume":"45","author":"Lim","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: prospective observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","article-title":"CAMERA2 study group. Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study","volume":"7","author":"Liu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/cid\/cis210","article-title":"Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer","volume":"54","author":"Theuretzbacher","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13318-019-00564-w","article-title":"Vancomycin pharmacokinetics in patients with advanced cancer near end of life","volume":"44","author":"Nakayama","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ckj\/sfs160","article-title":"The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review","volume":"6","author":"Lopes","year":"2013","journal-title":"Clin Kidney J"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FTD.0000000000000490","article-title":"Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis","volume":"40","author":"Goti","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"suppl 2","key":"R19-20260730","doi-asserted-by":"crossref","first-page":"S575","DOI":"10.1093\/ofid\/ofz360.1438","article-title":"1574. Predictive ability and bias of vancomycin population PK models in an Obese adult population","volume":"6","author":"Sabourenkov","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 1","key":"R20-20260730","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R21-20260730","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1078155209355847","article-title":"Pharmacokinetics of vancomycin in adult cancer patients","volume":"16","author":"Al-Kofide","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"R22-20260730","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1248\/bpb.32.99","article-title":"A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data","volume":"32","author":"Omote","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin- resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R27-20260730","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R28-20260730","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bcp.15301","article-title":"Impact of pharmacist intervention in reducing vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"89","author":"Kunming","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:01:24Z","timestamp":1785405684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001508","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2026-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}